Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.05 | 0.00 | 0.00 | 0.00 |
P/S ratio |
23.38 | 53.24 | 64.93 | 60.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.29) | 29.59 | (23.26) | (19.96) | |
P/B ratio |
1.39 | 3.90 | 8.27 | 0.00 | |
Price to Tangible BV |
1.39 | 3.90 | 8.27 | 0.00 | |
EV/Sales |
1.89 | 21.56 | 39.54 | 39.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.14) | (2.55) | (5.93) | (5.81) | |
EV/FCF |
(0.14) | (2.53) | (5.87) | (5.79) | |
Quick Ratio |
9.52 | 7.15 | 6.01 | 4.55 | |
Current Ratio |
9.83 | 7.35 | 6.15 | 4.70 | |
Net Debt/EBITDA |
5.68 | 8.94 | 7.96 | 6.77 | |
Debt/Assets |
0.05% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.04 | 0.05 | 0.06 | |
Operating CF/Net income |
0.74 | (0.16) | 0.60 | 0.38 | |
Capex/Depreciation |
0.09 | 0.00 | 0.00 | (0.25) | |
Research and Development Expense of Revenue |
1,176.86% | 2,401.44% | 785.16% | 608.04% | |
Selling, General and Administrative Expense of Revenue |
578.11% | 1,369.83% | 324.96% | 244.07% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
123.77% | 330.75% | 113.76% | 108.54% | |
Graham Net Nets |
0.61 | 0.24 | 0.11 | (0.02) | |
Graham Number |
55.62 | 0.00 | 0.00 | 0.79 | |
Earnings Yield |
2,130.89% | (43.39%) | (53.51%) | (53.09%) | |
Free Cash Flow Yield |
(58.22%) | (16.00%) | (10.37%) | (11.33%) | |
Revenue per Share |
0.03 | 0.01 | 0.02 | 0.03 | |
Operating CF per Share |
(0.41) | 0.21 | (0.19) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | 0.21 | (0.19) | (0.22) | |
Cash per Share |
2.76 | 3.65 | 1.73 | 1.50 | |
Shareholders Equity per Share |
2.15 | 1.57 | 0.53 | (0.01) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.15 | 1.57 | 0.53 | (0.01) | |
Free Cash Flow |
(11.18) | 6.29 | (10.98) | (12.81) | |
Working Capital |
69.81 | 98.58 | 85.57 | 70.89 | |
Capital Expenditures |
0.04 | 0.00 | — | (0.13) | |
Net Current Asset Value |
49.98 | 43.99 | 27.64 | (4.09) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.05) | 0.00 | 0.00 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.23 | 0.70 | 1.13 | 1.14 | |
Average Assets |
53.88 | 98.06 | 84.12 | 72.35 | |
Average Common Equity |
(50.15) | 55.42 | 41.24 | 19.65 |
Columns are period end dates